Wells Fargo Reiterates Overweight Rating on Nurix (NRIX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Nurix (NRIX) PT Raised to $34 at Stifel
October 14, 2024 8:33 AM UTC(Updated - October 14, 2024 8:34 AM EDT)
Stifel analyst Stephen Willey raised the price target on Nurix (NASDAQ: NRIX) to $34.00 (from $30.00) while maintaining a Buy rating.
The analyst commented: "We like implied risk/reward into the anticipated update of P1/1b NX-5948 data... More
Piper Sandler Reiterates Overweight Rating on Nurix (NRIX)
October 14, 2024 7:36 AM UTCPiper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $35.00 price target on Nurix (NASDAQ: NRIX).
The analyst commented, "NRIX reported 3Q24 earnings and provided a pipeline update. Most importantly, development of NX-5948 remains on track with two Phase Ia updates expected... More
Nurix Therapeutics, Inc. (NRIX) Reports In-Line Q3 EPS
October 14, 2024 3:50 AM UTCNurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q3 EPS of ($0.67), in-line with the analyst estimate of ($0.67). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $14.98 million.
For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.
... MoreJefferies Starts Nurix (NRIX) at Buy
October 11, 2024 5:25 AM UTCJefferies analyst Roger Song initiates coverage on Nurix (NASDAQ: NRIX) with a Buy rating and a price target of $41.00.
The analyst said: "NRIX focuses on targeted protein modulation for cancer and I&I. Lead '5948 (BTK degrader) aims to better address broad BTK... More
